Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission. ___________________________________ [i] 2011 United States Renal Data System Annual Data Report ( http://www.usrds.org/2011/view/default.asp). [ii] Ndip et al. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. Diabetes Care. 2012; 33:1811-1816. [iii] Policy Options for Kidney Health in Europe. European Kidney Health Alliance ( http://www.era-edta.org/images/2012_EKHA-policy_paper.pdf) [iv] Fistula First Breakthrough Initiative 2011 dashboard ( http://www.fistulafirst.org/AboutFistulaFirst/FFBIData.aspx) [v] National Kidney Foundation Kidney Disease Outcome Quality Initiative Guidelines ( http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm) [vi] Dixon et al. DAC Study Group.Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009; 360: 2191-2201. [vii] Hayashi et al. Vascular access for hemodialysis. Nat ClinPractNephrol. 2006; 2: 504-513. For further information please contact: Investor Relations Eric Rojas email@example.com +1-7814820999 Sarah Elton-Farr firstname.lastname@example.org +44-1256-894157 Media Jessica Mann (Corporate) email@example.com +44-1256-894-280 Lindsey Hart (Regenerative Medicine) firstname.lastname@example.org +1-615-250-3311 SOURCE Shire plc